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Conclusion: Peripheral dose for the Cyberknife® M6TM 
version is lower than previous Cyberknife® versions. 
Nevertheless, for a brain treatment the dose can reach 10 
cGy in the thyroid and can exceed 7 cGy in gonads; it should 
be evaluated for every localization. Peripheral dose will 
depend on number of monitor units, beam aperture size and 
collimator system. These parameters should be optimized 
during treatment planning to limit peripheral dose as lower 
as possible. 
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Purpose or Objective: Several dosimetric methods were 
proposed to overcome limitations of the standard dose index 
used for CT dosimetry (CTDI100) with cone beam computed 
tomography (CBCT). Two of these methods were proposed by 
IEC and AAPM. The aim of this project was to investigate the 
correlation between organ doses (ODs) resulting from head, 
thorax, and pelvic CBCT scans and the IEC and AAPM 
methods. 
 
Material and Methods: The IEC method (CTDIIEC) is based on 
measuring CTDI100 using a reference beam and the 
application of a correction factor based on free-in-air CTDI 
measurements, while the AAPM method f(0) is based on 
measuring cumulative dose using a small ionization chamber 
at the middle of an infinitely long phantom ≥450 mm. 
CTDIIEC was evaluated within CTDI head and body phantoms, 
whereas f(0) was assessed within 450 mm long CTDI 
phantoms. CTDIIEC and f(0) were measured at the centre and 
periphery of the phantoms using head, thorax, and pelvic 
scanning protocols used in the clinic. ODs were evaluated in 
terms of absorbed dose to organs and tissues using Monte 
Carlo simulations on the ICRP-110 adult male and female 
reference computational phantoms. BEAMnrc and DOSXYZnrc 
user codes were utilized to simulate On-Board Imager (OBI) 
system mounted on a TrueBeam linac and to assess ODs using 
the same scanning protocols used for CTDIIEC and f(0). The 
correlation was studied as the difference between weighed 
values (2/3 periphery:1/3 centre) of CTDIIEC,w and f(0)w and 
ODs. The correlation was investigated for organs, which have 
higher weights of effective dose.  
 
Results: For head scan, CTDIIEC,w were smaller than doses to 
bone marrow, brain, and salivary gland by 4-55% for male and 
by 16-84% for female. f(0)w was also smaller than doses to 
bone marrow and salivary gland by 7-26% and 49-50% for male 
and female, respectively, but was larger than brain dose by 
15% and 5%, respectively. For thorax scan, doses to bone 
marrow, lung, breast, and oesophagus were underestimated 
by CTDIIEC,w and f(0)w by 61-100% and 35-58% for male and 
by 108-161% and 64-106% for female, respectively. However, 
CTDIIEC,w and f(0)w overestimated doses to stomach and 
thyroid by 10-34% and 29-45% for male and by 13-28% and 31-
43% for female, respectively. For pelvic scan, CTDIIEC,w and 
f(0)w were smaller than doses to bone marrow and urinary 
bladder by 91-173% and 51-116%, respectively, but were 
larger than colon and gonads doses by 30-78% and 44-82%, 
respectively, for male. For female, however, doses to all the 
organs were underestimated by CTDIIEC,w and f(0)w by 76-
204% and 40-141%, respectively. 
 
Conclusion: The correlations between CTDIIEC,w and f(0)w 
and ODs were comparable to the majority of organs. In 
general, however, f(0)w gave a better estimation for ODs 
compared to CTDIIEC,w for the scanning protocols studied. 
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Purpose or Objective: An elevated risk of radiation-induced 
secondary cancer (SC) in directly irradiated tissues such as 
the bladder and rectum has been observed in prostate cancer 
patients following radiotherapy (RT). There are considerable 
fluctuations in SC risk due to inter-patient anatomy 
variations, indicating the relevance of also including the 
effects of internal organ motion for individual patients. Both 
the bladder and rectum are highly mobile structures and the 
aim of this study was therefore to investigate the influence 
of organ motion on SC risk. 
 
Material and Methods: Simultaneously integrated boost 
treatment plans were generated on the planning CT (pCT) 
scans of eight prostate patients, using volumetric modulated 
arc therapy (VMAT) and intensity-modulated proton therapy 
(IMPT). Both VMAT and IMPT plans were prescribed to deliver 
67.5 Gy to the prostate and 60 Gy to the seminal vesicles 
over 25 fractions, using fiducial marker based image 
guidance. Each patient had 8-9 repeat CT (rCT) scans 
throughout the course of treatment on which the bladder and 
rectum were re-contoured and the originally planned dose 
distribution re-calculated. Relative risk (RR) of radiation-
induced cancer were calculated from the planned and re-
calculated dose distributions by using the organ equivalent 
dose concept adapted to dose-response models reflecting 
varying degrees of cell sterilisation: a linear model, a linear-
plateau model and a bell-shaped competition model. 
 
Results: Using the competition model, the RRs of bladder 
cancer based on the pCTs ranged from 0.4 to 3.4, while a 
considerably wider range was found when including all rCTs 
(from 0.2 to 6.7). Similar trends were seen for the RR for 
rectal cancer with the competition model and also for both 
bladder and rectal cancer using the linear model (Fig 1). 
Overall, the ranges were narrower with the linear model 
compared to competition model (Fig 1). For 4/8 patients for 
the bladder and 1/8 patients for the rectum, the estimated 
risks according to the competition model were consistently 
lower for IMPT compared to VMAT. Using the linear model the 
corresponding fractions were 6/8 and 7/8 patients. The 
remaining patients had rCTs with variations in RR, favouring 
either VMAT or IMPT, except one of the patients with all rCTs 
in favour of VMAT for rectal cancer using the competition 
model. In particular for the competition model, the RRs 
according to the pCT were often found at the upper or lower 
side of the RR across rCTs and two cases for bladder cancer 
and three cases for rectal cancer had RR <1 when addressed 
with the pCT but a median RR>1 across the rCT. 
 
